Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: Results of the GO-FORWARD trial

Annals of the Rheumatic Diseases

Volumn 70, Issue 11, 2011, Pages 1968-1974

  Conaghan, Philip G ^a,b   Emery, Paul ^a,b   Østergaard, Mikkel ^c   Keystone, Edward C ^d   Genovese, Mark C ^e   Hsia, Elizabeth C ^f,g   Xu, Weichun ^f   Rahman, Mahboob U ^g,h  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b Chapel Allerton Hospital   (United Kingdom)

^c Mental Health Services CPH   (Denmark)

^d UNIVERSITY OF TORONTO   (Canada)

^e STANFORD UNIVERSITY   (United States)

^f CENTOCOR INC   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GOLIMUMAB; METHOTREXATE; PLACEBO;

ADULT; ARTICLE; BONE EROSION; COMBINATION CHEMOTHERAPY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG RESPONSE; FEMALE; HUMAN; INFLAMMATION; JOINT INJURY; MAJOR CLINICAL STUDY; MALE; METACARPOPHALANGEAL JOINT; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SYNOVITIS; WRIST;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; METACARPOPHALANGEAL JOINT; METHOTREXATE; MIDDLE AGED; OSTEITIS; SYNOVITIS; TREATMENT OUTCOME; WRIST JOINT;

EID: 80053563603     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.146068     Document Type: Article

References (29)

1. Keystone E C, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009;68:789-96.
2. Keystone E, Genovese MC, Klareskog L, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann Rheum Dis 2010;69:1129-35.
3. Emery P, Fleischmann R, van der Heijde D, et al. The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. Arthritis Rheum 2011;63:1200-10.
4. Giovagnoni A, Valeri G, Burroni E, et al. Rheumatoid arthritis: follow-up and response to treatment. Eur J Radiol 1998;27(Suppl 1):S25-30. (Pubitemid 28273250)
5. Peterfy CG. New developments in imaging in rheumatoid arthritis. Curr Opin Rheumatol 2003;15:288-95. (Pubitemid 36532609)
6. McQueen F, Lassere M, Edmonds J, et al. OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Summary of OMERACT 6 MR Imaging Module. J Rheumatol 2003;30:1387-92. (Pubitemid 36666374)
7. Hoving J L, Buchbinder R, Hall S, et al. A comparison of magnetic resonance imaging, sonography, and radiography of the hand in patients with early rheumatoid arthritis. J Rheumatol 2004;31:663-75. (Pubitemid 38451251)
8. Klarlund M, Ostergaard M, Jensen KE, et al. Magnetic resonance imaging, radiography, and scintigraphy of the fi nger joints: one year follow up of patients with early arthritis. The TIRA Group. Ann Rheum Dis 2000;59:521-8. (Pubitemid 30445830)
9. Østergaard M, Hansen M, Stoltenberg M, et al. New radiographic bone erosions in the wrists of patients with rheumatoid arthritis are detectable with magnetic resonance imaging a median of two years earlier. Arthritis Rheum 2003;48:2128-31. (Pubitemid 36959192)
10. Ejbjerg B J, Vestergaard A, Jacobsen S, et al. The smallest detectable difference and sensitivity to change of magnetic resonance imaging and radiographic scoring of structural joint damage in rheumatoid arthritis fi nger, wrist, and toe joints: a comparison of the OMERACT rheumatoid arthritis magnetic resonance imaging score applied to different joint combinations and the Sharp/van der Heijde radiographic score. Arthritis Rheum 2005;52:2300-6. (Pubitemid 41117413)
11. Dalbeth N, Smith T, Gray S, et al. Cellular characterisation of magnetic resonance imaging bone oedema in rheumatoid arthritis; implications for pathogenesis of erosive disease. Ann Rheum Dis 2009;68:279-82.
12. Conaghan P G, O'Connor P, McGonagle D, et al. Elucidation of the relationship between synovitis and bone damage: a randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis. Arthritis Rheum 2003;48:64-71. (Pubitemid 36091649)
13. Huang J, Stewart N, Crabbe J, et al. A 1-year follow-up study of dynamic magnetic resonance imaging in early rheumatoid arthritis reveals synovitis to be increased in shared epitope-positive patients and predictive of erosions at 1 year. Rheumatology (Oxford) 2000;39:407-16. (Pubitemid 30307327)
14. M cQueen F M, Benton N, Perry D, et al. B one edema scored on magnetic resonance imaging scans of the dominant carpus at presentation predicts radiographic joint damage of the hands and feet six years later in patients with rheumatoid arthritis. Arthritis Rheum 2003;48:1814-27.
15. Haavardsholm E A, Bøyesen P, ∅stergaard M, et al. Magnetic resonance imaging fi ndings in 84 patients with early rheumatoid arthritis: bone marrow oedema predicts erosive progression. Ann Rheum Dis 2008;67:794-800. (Pubitemid 351843277)
16. Hetland M L, Ejbjerg B, Hørslev-Petersen K, et al. M RI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA). Ann Rheum Dis 2009;68:384-90.
17. Hetland M L, Stengaard-Pedersen K, Junker P, et al. Radiographic progression and remission rates in early rheumatoid arthritis-MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial. Ann Rheum Dis 2010;69:1789-95.
18. Hodgson RJ, O'Connor P, Moots R. MRI of rheumatoid arthritis image quantitation for the assessment of disease activity, progression and response to therapy. Rheumatology (Oxford) 2008;47:13-21. (Pubitemid 350301006)
19. Bøyesen P, Haavardsholm EA, van der Heijde D, et al. Prediction of MRI erosive progression: a comparison of modern imaging modalities in early rheumatoid arthritis patients. Ann Rheum Dis 2011;70:176-9.
20. Østergaard M, Peterfy C, Conaghan P, et al. OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Core set of MRI acquisitions, joint pathology defi nitions, and the OMERACT RA-MRI scoring system. J Rheumatol 2003;30:1385-6. (Pubitemid 36666373)
21. Conover WJ. Practical Nonparametric Statistics . Third Edition . Hoboken, NJ:John Wiley & Sons, Inc 1999:396-406.
22. Vangeneugden T, Laenen A, Geys H, et al. Applying concepts of generalizability theory on clinical trial data to investigate sources of variation and their impact on reliability. Biometrics 2005;61:295-304. (Pubitemid 40380992)
23. Haavardsholm E A, Ostergaard M, Ejbjerg BJ, et al. Reliability and sensitivity to change of the OMERACT rheumatoid arthritis magnetic resonance imaging score in a multireader, longitudinal setting. Arthritis Rheum 2005;52:3860-7. (Pubitemid 41798224)
24. Rahman M U, Buchanan J, Doyle MK, et al. Historical trends of patient characteristics in anti-TNF clinical trials for rheumatoid arthritis: an analysis of the literature over the past 16 years [abstract] . Ann Rheum Dis 2010;69(Suppl 3):530.
25. Smolen J S, van Der Heijde DM, St Clair EW, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infl iximab: results from the ASPIRE trial. Arthritis Rheum 2006;54:702-10.
26. Keystone E, Heijde D, Mason D, Jr, et al. Certolizumab pegol plus methotrexate is signifi cantly more effective than placebo plus methotrexate in active rheumatoid arthritis: fi ndings of a fi fty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008;58:3319-29.
27. Ostergaard M, Emery P, Conaghan PG, et al. Golimumab and methotrexate combination therapy signifi cantly improve synovitis, osteitis and bone erosion compared with methotrexate alone-a magnetic resonance imaging study of 318 methotrexate-naïve rheumatoid arthritis patients. Arthritis Rheum.
28. Døhn U M, Ejbjerg B, Boonen A, et al. No overall progression and occasional repair of erosions despite persistent infl ammation in adalimumab-treated rheumatoid arthritis patients: results from a longitudinal comparative MRI, ultrasonography, CT and radiography study. Ann Rheum Dis 2011;70:252-8.
29. Mundwiler M L, Maranian P, Brown DH, et al. The utility of MRI in predicting radiographic erosions in the metatarsophalangeal joints of the rheumatoid foot: a prospective longitudinal cohort study. Arthritis Res Ther 2009;11:R94.